vs
Side-by-side financial comparison of ESAB Corp (ESAB) and PERRIGO Co plc (PRGO). Click either name above to swap in a different company.
PERRIGO Co plc is the larger business by last-quarter revenue ($1.1B vs $727.8M, roughly 1.5× ESAB Corp). ESAB Corp runs the higher net margin — 7.5% vs -127.8%, a 135.3% gap on every dollar of revenue. On growth, ESAB Corp posted the faster year-over-year revenue change (8.5% vs -2.5%). PERRIGO Co plc produced more free cash flow last quarter ($148.6M vs $70.3M). Over the past eight quarters, ESAB Corp's revenue compounded faster (2.8% CAGR vs 1.3%).
ESAB, Elektriska Svetsnings-Aktiebolaget, is an American-Swedish industrial company.
Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters ...
ESAB vs PRGO — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $727.8M | $1.1B |
| Net Profit | $54.8M | $-1.4B |
| Gross Margin | 37.0% | 32.6% |
| Operating Margin | 14.6% | -116.0% |
| Net Margin | 7.5% | -127.8% |
| Revenue YoY | 8.5% | -2.5% |
| Net Profit YoY | 2.1% | -3093.9% |
| EPS (diluted) | $0.90 | $-10.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $727.8M | $1.1B | ||
| Q3 25 | $715.6M | $1.0B | ||
| Q2 25 | $678.1M | $1.1B | ||
| Q1 25 | — | $1.0B | ||
| Q4 24 | $670.8M | $1.1B | ||
| Q3 24 | $673.3M | $1.1B | ||
| Q2 24 | $707.1M | $1.1B | ||
| Q1 24 | $689.7M | $1.1B |
| Q4 25 | $54.8M | $-1.4B | ||
| Q3 25 | $66.9M | $7.5M | ||
| Q2 25 | $67.4M | $-8.4M | ||
| Q1 25 | — | $-6.4M | ||
| Q4 24 | $53.7M | $-44.4M | ||
| Q3 24 | $68.2M | $-21.0M | ||
| Q2 24 | $82.9M | $-108.4M | ||
| Q1 24 | $60.0M | $2.0M |
| Q4 25 | 37.0% | 32.6% | ||
| Q3 25 | 37.2% | 36.1% | ||
| Q2 25 | 37.6% | 34.4% | ||
| Q1 25 | — | 37.6% | ||
| Q4 24 | 38.5% | 33.9% | ||
| Q3 24 | 37.7% | 37.2% | ||
| Q2 24 | 38.2% | 37.0% | ||
| Q1 24 | 37.0% | 33.1% |
| Q4 25 | 14.6% | -116.0% | ||
| Q3 25 | 15.2% | 7.0% | ||
| Q2 25 | 16.2% | 4.3% | ||
| Q1 25 | — | 4.5% | ||
| Q4 24 | 16.6% | 10.0% | ||
| Q3 24 | 15.7% | 7.4% | ||
| Q2 24 | 16.9% | -2.5% | ||
| Q1 24 | 16.0% | -5.1% |
| Q4 25 | 7.5% | -127.8% | ||
| Q3 25 | 9.3% | 0.7% | ||
| Q2 25 | 9.9% | -0.8% | ||
| Q1 25 | — | -0.6% | ||
| Q4 24 | 8.0% | -3.9% | ||
| Q3 24 | 10.1% | -1.9% | ||
| Q2 24 | 11.7% | -10.2% | ||
| Q1 24 | 8.7% | 0.2% |
| Q4 25 | $0.90 | $-10.23 | ||
| Q3 25 | $1.09 | $0.05 | ||
| Q2 25 | $1.10 | $-0.06 | ||
| Q1 25 | — | $-0.05 | ||
| Q4 24 | $0.87 | $-0.32 | ||
| Q3 24 | $1.11 | $-0.15 | ||
| Q2 24 | $1.35 | $-0.79 | ||
| Q1 24 | $0.98 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $218.2M | — |
| Total DebtLower is stronger | $1.3B | — |
| Stockholders' EquityBook value | $2.1B | $2.9B |
| Total Assets | $4.9B | $8.5B |
| Debt / EquityLower = less leverage | 0.63× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $218.2M | — | ||
| Q3 25 | $258.2M | $432.1M | ||
| Q2 25 | $291.3M | $454.2M | ||
| Q1 25 | — | $409.9M | ||
| Q4 24 | $249.4M | $558.8M | ||
| Q3 24 | $253.7M | $1.5B | ||
| Q2 24 | $228.5M | $542.8M | ||
| Q1 24 | $76.5M | $658.5M |
| Q4 25 | $1.3B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $1.1B | — | ||
| Q1 24 | $992.8M | — |
| Q4 25 | $2.1B | $2.9B | ||
| Q3 25 | $2.1B | $4.4B | ||
| Q2 25 | $1.9B | $4.5B | ||
| Q1 25 | — | $4.4B | ||
| Q4 24 | $1.8B | $4.3B | ||
| Q3 24 | $1.8B | $4.6B | ||
| Q2 24 | $1.7B | $4.5B | ||
| Q1 24 | $1.6B | $4.7B |
| Q4 25 | $4.9B | $8.5B | ||
| Q3 25 | $4.4B | $10.1B | ||
| Q2 25 | $4.2B | $10.1B | ||
| Q1 25 | — | $9.8B | ||
| Q4 24 | $4.0B | $9.6B | ||
| Q3 24 | $4.1B | $11.2B | ||
| Q2 24 | $4.0B | $10.4B | ||
| Q1 24 | $3.8B | $10.6B |
| Q4 25 | 0.63× | — | ||
| Q3 25 | 0.51× | — | ||
| Q2 25 | 0.55× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.60× | — | ||
| Q3 24 | 0.59× | — | ||
| Q2 24 | 0.63× | — | ||
| Q1 24 | 0.61× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $81.5M | $175.4M |
| Free Cash FlowOCF − Capex | $70.3M | $148.6M |
| FCF MarginFCF / Revenue | 9.7% | 13.4% |
| Capex IntensityCapex / Revenue | 1.5% | 2.4% |
| Cash ConversionOCF / Net Profit | 1.49× | — |
| TTM Free Cash FlowTrailing 4 quarters | $238.0M | $145.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $81.5M | $175.4M | ||
| Q3 25 | $46.6M | $51.7M | ||
| Q2 25 | $35.4M | $75.9M | ||
| Q1 25 | — | $-64.5M | ||
| Q4 24 | $126.9M | $312.6M | ||
| Q3 24 | $101.0M | $42.2M | ||
| Q2 24 | $83.0M | $9.5M | ||
| Q1 24 | $44.5M | $-1.4M |
| Q4 25 | $70.3M | $148.6M | ||
| Q3 25 | $37.4M | $29.8M | ||
| Q2 25 | $28.1M | $56.7M | ||
| Q1 25 | — | $-90.0M | ||
| Q4 24 | $102.2M | $274.9M | ||
| Q3 24 | $90.4M | $15.1M | ||
| Q2 24 | $74.0M | $-18.9M | ||
| Q1 24 | $37.1M | $-26.5M |
| Q4 25 | 9.7% | 13.4% | ||
| Q3 25 | 5.2% | 2.9% | ||
| Q2 25 | 4.1% | 5.4% | ||
| Q1 25 | — | -8.6% | ||
| Q4 24 | 15.2% | 24.2% | ||
| Q3 24 | 13.4% | 1.4% | ||
| Q2 24 | 10.5% | -1.8% | ||
| Q1 24 | 5.4% | -2.4% |
| Q4 25 | 1.5% | 2.4% | ||
| Q3 25 | 1.3% | 2.1% | ||
| Q2 25 | 1.1% | 1.8% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | 3.7% | 3.3% | ||
| Q3 24 | 1.6% | 2.5% | ||
| Q2 24 | 1.3% | 2.7% | ||
| Q1 24 | 1.1% | 2.3% |
| Q4 25 | 1.49× | — | ||
| Q3 25 | 0.70× | 6.89× | ||
| Q2 25 | 0.53× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 2.36× | — | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.00× | — | ||
| Q1 24 | 0.74× | -0.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESAB
| Consumable Products | $477.9M | 66% |
| Equipment Products | $249.9M | 34% |
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
